Pfizer’s anti-viral Covid-19 pill that is aimed at treating those at risk of severe illness has gotten a conditional green light from The European Union’s drug regulator.
Italy, Germany and Belgium are countries that have bought the drug. The branding of the drug has been confirmed as Paxlovid.
In December the US authorised Paxloid. Mercks’s Covid-19 pill is also under review in the EU due to data in November that says the drug is less effective than first thought.
Paxlovid is a two-drug antiviral regimen that has been seen as 90% effective in preventing hospitalisations and deaths in people that are in the high risk catagory in the clinical trial.